Related Experiment Video
Updated: May 22, 2026
07:32
Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
Published on: May 23, 2025
Sub-lethal levels of amyloid β-peptide oligomers decrease non-transferrin-bound iron uptake and do not potentiate
C D SanMartín1, A C Paula-Lima, C Hidalgo
1Facultad de Medicina, Center for Molecular Studies of the Cell, Universidad de Chile, Santiago, Chile.
Summary
Alzheimer's disease (AD) research shows amyloid beta oligomers (AβOs) reduce iron uptake by decreasing DMT1 (-)IRE mRNA. However, AβOs and iron do not synergistically increase neurotoxicity, suggesting a common pathway in AD pathogenesis.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Alzheimer's disease (AD) is characterized by neurofibrillary tangles and amyloid plaques.
- Soluble amyloid beta oligomers (AβOs) are implicated as key neurotoxic agents in AD.
- Metal ions like iron accumulate in AD lesions and contribute to oxidative stress.
Purpose of the Study:
- To investigate the effect of AβOs on the divalent metal transporter 1 (DMT1) in hippocampal neurons.
- To determine if iron and AβOs exhibit synergistic neurotoxic effects.
Main Methods:
- Primary hippocampal neuron cultures were treated with AβOs.
- DMT1 (+)IRE and (-)IRE mRNA levels were analyzed.
- Non-transferrin bound iron uptake was measured.
- Cell death assays were performed to assess iron and AβO synergy.
Main Results:
- Non-lethal AβO concentrations decreased DMT1 (-)IRE mRNA levels.
- AβOs inhibited non-transferrin bound iron uptake.
- AβOs did not potentiate iron-induced cell death, and iron chelation did not reduce AβO-induced cell death.
Conclusions:
- AβOs impact iron transport regulation in neurons by downregulating DMT1 (-)IRE.
- The lack of synergistic toxicity between iron and AβOs suggests a shared downstream signaling pathway in neurodegeneration.
